Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723, an oral HPK1-targeting PROTAC, as monotherapy and with pembrolizumab in advanced solid tumors.Material DetailsContext by AI AnalystThis is an early-stage clinical milestone expanding Arvinas’ PROTAC platform into immuno-oncology. For…
The study will generate initial safety, drug-behavior and early antitumor readouts. ARV-6723 is being tested alone and with pembrolizumab in patients previously treated with checkpoint inhibitors.
Arvinas said the first patient has been dosed in its phase 1/2 clinical trial of ARV-6723, its first immuno-oncology candidate.
Arvinas (NASDAQ: ARVN ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Arvinas Inc. reported